Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.

High-resolution cross-sectional imaging improved dramatically the diagnosis and therapy management of oncological patients, although several questions remained open, primarily concerning the exact initial staging, the differential diagnosis of recurrent tumors, and therapy management. Positron emission tomography (PET) is a quantitative, functional imaging modality from the field of nuclear medicine which has the potential to yield physiological information. The diagnosis of tumors with PET is based on the increased regional glucose metabolism. Furthermore, PET can serve as a valuable tool for monitoring therapeutic effects. The most common tracer used for oncological studies is F-18-deoxyglucose (FDG), a glucose analog. FDG-PET has been evaluated in different tumor types such as colorectal cancer, malignant lymphomas, melanomas, soft-tissue sarcomas, and lung tumors for both the diagnosis of primary tumors and recurrent lesions. The sensitivity of PET-FDG studies exceeds 85%, dependent on tumor type, size, and location. The diagnosis of viable tumor tissue following chemotherapy is another application of PET. A limitation of FDG-PET studies is false positive results, e.g., due to inflammation. This problem may be overcome by the use of multitracer studies and/or labeled amino acids. Different procedures can be used to evaluate therapeutic effects. FDG follow-up studies are used to assess early effects and to predict long-term response. Pharmacokinetic studies of labeled therapeutic agents such as F-18-fluorouracil or C-11-ethanol provide exclusively quantitative data about transport and elimination of a drug. PET with labeled cytostatic drugs permits a prognosis prior to onset of chemotherapy. This procedure is recommended for monochemotherapy. In patients receiving polychemotherapy, the evaluation of different resistance mechanisms is needed and new approaches using suitable substrates, e.g., for the P-glycoprotein, are being developed or are already in use for scientific purposes.

[1]  L. Mortelmans,et al.  Clinical value of whole‐body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer , 1994, The British journal of surgery.

[2]  Georgios Kontaxakis Maximum likelihood image reconstruction in positron emission tomography (PET):\sConvergence characteristics and stopping rules , 1997 .

[3]  K. Follett,et al.  Diagnosis of Recurrent Brain , 1994 .

[4]  A. Willemsen,et al.  Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. , 1995, Radiology.

[5]  H. Minn,et al.  Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[6]  M Schwaiger,et al.  Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  P. Marsden,et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer , 1994, The Lancet.

[9]  H. Friess,et al.  2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. , 1995, Radiology.

[10]  G van Kaick,et al.  Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[12]  D. Podoloff,et al.  Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Dimitrakopoulou-Strauss,et al.  Die Positronenemissionstomographie (PET) bei der Diagnostik und Therapieplanung von malignen Lymphomen , 1997 .

[14]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. van Kaick,et al.  Positron emission tomography (PET) for diagnosis and therapy management of malignant lymphomas , 1997, Der Radiologe.

[16]  P. M. Falk,et al.  Pre-operative staging of colorectal carcinoma using positron emission tomography. , 1993, The Nebraska medical journal.

[17]  N. Gupta,et al.  PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. , 1995, Chest.

[18]  Γεωργιοσ Κονταξακησ MAXIMUM LIKELIHOOD IMAGE RECONSTRUCTION IN POSITRON EMISSION TOMOGRAPHY: CONVERGENCE CHARACTERISTICS AND STOPPING RULES , 1996 .

[19]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.

[20]  G. van Kaick,et al.  Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  R. Wahl,et al.  Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Strother,et al.  [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.